ERBB2 and breast cancer: Moreover, the mutation of the MED1 phosphorylation sites (T > A) on T1032 and T1457 in those BC cell lines overexpressing HER2 and tamoxifen-resistant, results in restored tamoxifen-sensitive and tamoxifen-induced N-CoR and SMRT recruitment [95].